Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

Author(s): Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, et al.

Abstract

Objective: To determine the prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetic population and to compare the prevalence of cardiovascular disease (CVD) and its risk factors between people with and without NAFLD.

Research design and methods: The entire sample of type 2 diabetic outpatients (n = 2,839) who regularly attended our clinic was screened. Main outcome measures were NAFLD (by patient history and liver ultrasound) and manifest CVD (by patient history, review of patient records, electrocardiogram, and echo-Doppler scanning of carotid and lower limb arteries).

Results: The unadjusted prevalence of NAFLD was 69.5% among participants, and NAFLD was the most common cause (81.5%) of hepatic steatosis on ultrasound examination. The prevalence of NAFLD increased with age (65.4% among participants aged 40-59 years and 74.6% among those aged > or = 60 years; P < 0.001) and the age-adjusted prevalence of NAFLD was 71.1% in men and 68% in women. NAFLD patients had remarkably (P < 0.001) higher age and sex-adjusted prevalences of coronary (26.6 vs. 18.3%), cerebrovascular (20.0 vs. 13.3%), and peripheral (15.4 vs. 10.0%) vascular disease than their counterparts without NAFLD. In logistic regression analysis, NAFLD was associated with prevalent CVD independent of classical risk factors, glycemic control, medications, and metabolic syndrome features.

Conclusions: NAFLD is extremely common in people with type 2 diabetes and is associated with a higher prevalence of CVD. Follow-up studies are needed to determine whether NAFLD predicts the development and progression of CVD.

Similar Articles

Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review

Author(s): Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, et al.

Gut microbiota and non-alcoholic fatty liver disease: new insights

Author(s): Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Author(s): Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al.

Increased oxidative stress in obesity and its impact on metabolic syndrome

Author(s): Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al.

Role of gut microbiota: obesity and NAFLD

Author(s): Gangarapu V, Yıldız K, Ince AT, Baysal B

Hepatic histology in obese patients undergoing bariatric surgery

Author(s): Machado M, Marques-Vidal P, Cortez-Pinto H

Gut microbiota and liver disease

Author(s): Goel A, Gupta M, Aggarwal R

An obesity-associated gut microbiome with increased capacity for energy harvest

Author(s): Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al.

Obesity alters gut microbial ecology

Author(s): Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, et al.

Microbial ecology: human gut microbes associated with obesity

Author(s): Ley RE, Turnbaugh PJ, Klein S, Gordon JI

Microbiota and SCFA in lean and overweight healthy subjects

Author(s): Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, et al.

Human colonic microbiota associated with diet, obesity and weight loss

Author(s): Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, et al.

Enterotypes of the human gut microbiome

Author(s): Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, et al.

The gut microbiota as an environmental factor that regulates fat storage

Author(s): Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al.

Mechanisms underlying the resistance to diet-induced obesity in germ-free mice

Author(s): Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI

Human gut microbiota in obesity and after gastric bypass

Author(s): Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, et al.

The gut microbiota, obesity and insulin resistance

Author(s): Shen J, Obin MS, Zhao L

Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice

Author(s): Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, et al.

The role of gut microbiota on insulin resistance

Author(s): Caricilli AM, Saad MJ

Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance

Author(s): Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al.

NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance

Author(s): Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, et al.

Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis

Author(s): Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, et al.

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice

Author(s): Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al.

Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis

Author(s): Rivera CA, Gaskin L, Allman M, Pang J, Brady K, et al.

Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5

Author(s): Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, et al.

NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis

Author(s): Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, et al.

A functional role for Nlrp6 in intestinal inflammation and tumorigenesis

Author(s): Chen GY, Liu M, Wang F, Bertin J, Núñez G

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Author(s): Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al.

NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion

Author(s): Wlodarska M, Thaiss CA2, Nowarski R3, Henao-Mejia J3, Zhang JP4, et al.

NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens

Author(s): Anand PK, Malireddi RK, Lukens JR, Vogel P, Bertin J, et al.

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin

Author(s): Bergheim I, Weber S, Vos M, Krämer S, Volynets V, et al.

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

Author(s): Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB

Review article: prebiotics in the gastrointestinal tract

Author(s): Macfarlane S, Macfarlane GT, Cummings JH

Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis

Author(s): Ma YY, Li L, Yu CH, Shen Z, Chen LH, et al.